Hosta

by | Mar 16, 2018 | Hosta

How Can We Help?
You are here:
< Back

Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40.[2] As of 2009, it has not entered clinical trials.[2]

References

  1. ^ International Nonproprietary Names For Pharmaceutical Substances
  2. ^ a b Law CL, Grewal IS (2009). "Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges". Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology. Vol. 647. New York, N.Y.: Springer Science+Business Media. pp. 8–36. doi:10.1007/978-0-387-89520-8_2. ISBN 978-0-387-89520-8. PMID 19760064.


Categories
Table of Contents